NTLA - intelliatx.com Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The EV/EBITDA ratio of Intellia Therapeutics (NTLA) on the financial timeline demonstrates the impact of a diversified CRISPR therapy portfolio developed in collaboration with Regeneron to minimize costs. The current mark is 0.00. The asset's value depends on the outcome of patent wars with biotech behemoths. Meanwhile, growth potential is based on breakthrough treatments for hereditary pathologies currently undergoing clinical trials.
Comprehensive metric breakdowns and analytics for intelliatx.com (NTLA)
- market price and analyst price targets:
- market capitalization statistics:
- book value of equity indicators:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Intellia Therapeutics|NTLA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Intellia Therapeutics, Inc.|NTLA - Company Cumulative Indebtedness|Debts to Book Capitalization Intellia Corp|NTLA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Intellia Therapeutics|Quick Liquidity intelliatx.com
- financial results and valuation multiples details:
NTLA - Final Profit|Projected Future Earnings Intellia Therapeutics|NTLA - P/E Multiple|Future Price to Earnings Intellia Therapeutics|NTLA - Market Cap to Earnings and Growth Ratio|EV/EBITDA Multiple Intellia Corp|NTLA - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Intellia Therapeutics|NTLA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months intelliatx.com|NTLA - Net earnings per one share growth for the current year|Earnings growth forecast for next year Intellia Therapeutics
- sales volume and revenue indicators:
General company analysis:Intellia NTLA
The resilience of Intellia Therapeutics (NTLA) is based on the non-cyclical nature of CRISPR technologies, where success is determined by clinical data rather than macroeconomics. This EV/EBITDA multiple compares the total asset price to its cash flow before taxes and depreciation, reflecting the efficiency of capital management. Analyzing this indicator allows an investor to assess the risk of overpayment or the probability of issuer default.
Key competitors
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Qiagen Corp - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RGEN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RNA: EV/EBITDA Multiple|CRSP - Total Company Value to Operating Income Before Depreciation Ratio|WGS (Sema4) - EV/EBITDA Multiple|EV/EBITDA Multiple Ultragenyx Corp|Enterprise Value to EBITDA Ratio BEAM (Beam Therapeutics Inc.)|SRPT (sarepta.com) - Business Value to Operating Income Before Depreciation|Twist Bioscience, Inc. - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio TXG (10x Genomics Inc)|Stoke - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation BLFS (BioLife)|WVE: EV/EBITDA Multiple|Company Value to EBITDA mazetx.com (MAZE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sionna Therapeutics|PRME: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple TSHA|EV/EBITDA Multiple uniQure Pharma (QURE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MeiraGTx Holdings plc MGTX|RGNX (regenxbio.com) - Company Value to Operating Income Before Depreciation Ratio|Solid Biosciences - EV/EBITDA Multiple|Company Value to EBITDA Ocugen Inc|PACB (Pacific Biosciences of California) - Enterprise Value to EBITDA Ratio|Benitec Corp (BNTC) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio DSGN|RCKT (rocketpharma.com) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple FDMT|Total Company Value to Operating Income Before Depreciation Ratio lexeotx.com|EV/EBITDA Multiple KRRO (Korro Bio)|EDIT - Enterprise Value to EBITDA Ratio|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ProQR Therapeutics N.V. PRQR|codexis.com (CDXS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation SGMO|Enterprise Value to EBITDA Ratio NAUT|MGX (Metagenomi Therapeutics) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences (DTIL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GBIO (generationbio.com)|EV/EBITDA Multiple BOLD (Boundless Bio)|EV/EBITDA Multiple Exicure Inc. XCUR|Celsion Corporation - EV/EBITDA Multiple|PHIO (Phio Pharmaceuticals) - Enterprise Value to Operating Income Before Depreciation|mustangbio.com (MBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Sciences Inc|EV/EBITDA Multiple BLUE|Total Company Value to Operating Income Before Depreciation Ratio immunoprecise.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS: Enterprise Value to EBITDA Ratio|Syros Pharmaceuticals Inc. - Enterprise Value to Operating Income Before Depreciation Ratio|TBIO: EV/EBITDA Multiple|Company Value to EBITDA TRACON Pharmaceuticals, Inc (TCON)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
